In the meantime, Bernstein upgraded its Novo Nordisk ADR [NVO] rating to a Mkt perform from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in late May with a ‘”a Buy”‘ rating. BMO Capital Markets began covering NVO with “an Outperform” recommendation on April 12, 2024. Morgan Stanley started covering the stock on January 23, 2024. It rated NVO as “an Overweight”.
Price Performance Review of NVO
On Tuesday, Novo Nordisk ADR [NYSE:NVO] saw its stock fall -1.99% to $83.34. Over the last five days, the stock has lost -2.79%. Novo Nordisk ADR shares have fallen nearly -3.12% since the year began. Nevertheless, the stocks have fallen -21.36% over the past one year. While a 52-week high of $148.15 was reached on 01/02/25, a 52-week low of $81.50 was recorded on 01/07/25. SMA at 50 days reached $103.10, while 200 days put it at $123.96.
Levels Of Support And Resistance For NVO Stock
The 24-hour chart illustrates a support level at 82.38, which if violated will result in even more drops to 81.43. On the upside, there is a resistance level at 84.55. A further resistance level may holdings at 85.77. The Relative Strength Index (RSI) on the 14-day chart is 25.67, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -5.29, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.32%. Stochastics %K at 13.60% indicates the stock is a buying.
How much short interest is there in Novo Nordisk ADR?
A steep rise in short interest was recorded in Novo Nordisk ADR stocks on 2024-12-13, dropping by -0.23 million shares to a total of 4.7 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 4.93 million shares. There was a decline of -4.9%, which implies that there is a negative sentiment for the stock.
